Amgen Inc. has announced positive topline results from the Phase 3 FORTITUDE-101 clinical trial, which evaluated the efficacy of bemarituzumab plus chemotherapy in patients with FGFR2b overexpression in first-line gastric cancer. The trial met its primary endpoint, showing a significant improvement in overall survival compared to chemotherapy alone. The most common adverse events in this treatment group included reduced visual acuity, punctate keratitis, and anemia among others. Detailed results from the study are set to be presented at a future medical meeting. Additionally, a Phase 3 study involving bemarituzumab, chemotherapy, and nivolumab is currently ongoing, with results expected in the second half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.